A medical professional has raised concerns about the use of GLP-1 weight loss drugs in children as young as six, citing potential risks involved in trying to prevent lifelong obesity.
The Centers for Disease Control and Prevention (CDC) data reveals that GLP-1s are being administered to elementary school children, despite lacking approval for treating such young patients.
Some physicians are prescribing these drugs off-label to young children to mitigate obesity-related health issues like high blood pressure and Type 2 diabetes, according to The Wall Street Journal.
While these medications are sanctioned to combat obesity in children from age 12, trials are underway for children as young as six. Additionally, GLP-1s have been approved for children aged 10 and older who have Type 2 diabetes in the US.
A doctor has expressed concern about using these drugs and cautions against their use for cosmetic purposes.
Dr Suzanne Wylie, a GP and medical adviser for IQdoctor, explained to UNILAD: “As a GP, I think it is important to begin by saying that GLP-1 medications should not be viewed as cosmetic weight loss treatments for children, because they are powerful prescription medicines that have a legitimate role in managing obesity in carefully selected young people, but only under specialist medical supervision and as part of a much broader treatment plan rather than as a quick fix.
“There has understandably been growing public interest in these drugs because of their success in adults, but children are still growing physically, hormonally and emotionally, which means the decision to prescribe them requires much more careful consideration than it does in an adult.”
Dr Wylie emphasized the lack of long-term safety data for children, which we have for adults, particularly regarding potential effects on growth and development over many years. “While studies have shown that GLP-1 medications can be effective in reducing weight in adolescents with obesity, there are still unanswered questions about what prolonged treatment during childhood might mean, which is why these medicines should never be used casually or without specialist oversight.”
According to CDC data, about 21 percent of US children aged two to 19 are considered obese.
Dr Wylie also highlights the nutritional concerns, noting that children require more nutrients than adults for proper growth. “Another issue is that children have much higher nutritional requirements than adults because they are building bone, muscle and other tissues throughout adolescence, and these medications work by reducing appetite and slowing stomach emptying.
“If a young person is eating significantly less without careful dietary support, there is a genuine risk that they may not consume enough protein, vitamins and minerals to support healthy growth, which is why dieticians form such an important part of any specialist obesity service looking after these patients.”
She also warns of the potential for more severe side effects in children and the psychological implications of relying on medication. “There are also the more familiar side effects that we see in adults, including nausea, vomiting, abdominal pain, constipation and diarrhoea, all of which can be particularly difficult for younger patients to tolerate,” she notes.
“In some cases, these side effects can become severe enough to affect hydration, school attendance and overall quality of life, while rarer complications, such as gallbladder disease or pancreatitis, although uncommon, remain important risks that need to be discussed before treatment begins.”
From a psychological angle, she stresses the importance of not conveying that medication is a catch-all solution for weight issues in childhood. “From a psychological perspective, it is equally important that we do not send the message that medication is the answer to every weight concern during childhood, because many young people are already vulnerable to low self-esteem, bullying and poor body image. If medicines are introduced without addressing emotional wellbeing, eating behaviours, physical activity, family habits and the wider social factors contributing to obesity, then we risk treating only one part of a much more complex condition. Children need support that helps them develop healthy lifelong habits rather than relying solely on medication.”
In the UK, medication is typically reserved for more severe cases, Dr Wylie mentions. She explains: “It is also worth remembering that not every child who is overweight requires drug treatment.
“In UK practice, medication is generally reserved for young people with significant obesity who are at risk of developing serious health complications and who have been assessed by specialist multidisciplinary teams. That assessment looks beyond a child’s weight alone and considers their overall health, medical history, psychological wellbeing and family circumstances before deciding whether the potential benefits outweigh the risks.”
Ultimately, Dr Wylie acknowledges the role of these medications but stresses the importance of professional oversight. “Ultimately, these medications do have an important place in modern obesity treatment for carefully selected young people, and for some families, they can genuinely be life-changing by reducing the risk of conditions such as type 2 diabetes, high blood pressure and fatty liver disease. However, they should never be seen as an easy solution or something that parents should seek independently through unregulated sources, because the safest and most effective use of GLP-1 medicines in children comes through specialist medical care, ongoing monitoring and comprehensive lifestyle support, with the aim of improving a child’s long-term health rather than simply reducing the number on the scales.”